Viva Biotech Holdings (FRA:VB0) Preferred Stock: €0.0 Mil (As of Dec. 2025)


FRA:VB0 Viva Biotech Holdings FRA:VB0
42 GF Score
Price €0.13
GF Value €0.08
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Viva Biotech Holdings Preferred Stock?

Viva Biotech Holdings FRA:VB0 -2.26% 42 Preferred Stock is €0.0 Mil as of Dec. 2025. GuruFocus rates FRA:VB0 with a GF Score™ of 42/100 and a GF Value™ of €0.08 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Preferred stock is a special equity security that has properties of both equity and debt. Viva Biotech Holdings's preferred stock for the quarter that ended in Dec. 2025 was €0.0 Mil.

The market value of preferred stock needs to be added to the market value of common stocks in the calculation of Enterprise Value. Viva Biotech Holdings's Enterprise Value for the quarter that ended in Dec. 2025 was €433.4 Mil.

In the calculation of book value, the par value of preferred stocks needs to subtracted from total equity. Viva Biotech Holdings's Book Value per Share for the quarter that ended in Dec. 2025 was €0.23.

Dividends paid to preferred stocks need to be subtracted from net income in the calculation of Earnings per Share (Diluted). Viva Biotech Holdings's Earnings per Share (Diluted) for the six months ended in Dec. 2025 was €0.01.


Viva Biotech Holdings  (FRA:VB0) Preferred Stock Explanation

When a company needs capital but does not wish to issue debt, they may sell preferred stocks to investors.

For instance, during the financial crisis of 2008, Goldman Sachs (GS) issued a combination of preferred stock and common stock options for $5 billion of capital to Warren Buffett’s Berkshire Hathaway (BRK.A)(BRK.B). In this deal, Berkshire Hathaway paid $5 billion for 10% cumulative perpetual preferred stock and warrants to buy 43.5 million shares of Goldman Sachs at $115 a share. Goldman Sachs bought back the preferred in 2010. Guess how much money Warren Buffett made in this deal in two years? Read How Much Did Warren Buffett’s Berkshire Hathaway (BRK.B) Make on Its Goldman Sachs (GS) Preferred Stock?

1. The market value of Preferred Stocks needs to be added to the market value of common stocks in the calculation of enterprise value.

Viva Biotech Holdings's Enterprise Value for the quarter that ended in Dec. 2025 is calculated as

2. In the calculation of Book Value, the par value of Preferred Stocks needs to subtracted from total equity.

Viva Biotech Holdings's Book Value per Share for the quarter that ended in Dec. 2025 is calculated as

3. Dividends paid to Preferred Stocks need to be subtracted from net income in the calculation of earnings per share.

Viva Biotech Holdings's Earnings per Share (Diluted) (EPS) for the six months ended in Dec. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Viva Biotech Holdings Preferred Stock Related Terms


Viva Biotech Holdings Preferred Stock Historical Data

* Premium members only.

The historical data trend for Viva Biotech Holdings's Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viva Biotech Holdings Preferred Stock Chart

Viva Biotech Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Preferred Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Viva Biotech Holdings Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Preferred Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:VB0
42GF Score
Viva Biotech Holdings FRA:VB0
Preferred Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viva Biotech Holdings Preferred Stock Calculation

Preferred Stock is a special equity security that has properties of both equity and debt. It is generally considered a hybrid instrument. Preferred stock is senior to common stock, but is subordinate to bonds in terms of claim or rights to their share of the assets of the company.

Preferred stock has priority over common stock in the payment of dividends and any payments received when a company liquidates.

Preferred stock comes in many forms. It can be:


Convertible or Non-Convertible
Cumulative or Non-Cumulative
Voting or Non-Voting
Callable or Non-Callable
Maturity Date or No Maturity Date

A preferred stock without a maturity date is called a perpetual preferred stock. These are relatively rare. A good example of perpetual preferred stock is the many series of Public Storage (PSA) preferred shares that trade on the New York Stock Exchange.

Before investing in preferred stock, it is important to know which of the above groups the stock belongs to. Is it convertible or non-convertible? Are dividends cumulative or non-cumulative?

It is also critical that an investor knows what bonds the company has in front of the preferred stock. Bondholders get paid first. So the decision to buy a preferred stock can be similar to the decision to buy a bond. But, remember, the preferred stock of a company with bonds is junior to those bonds.

Unless a preferred stock is convertible, the upside in a preferred stock investment is more limited than in a common stock investment. If a company doubles its earnings, it is usually under no more obligation to double the dividends paid to preferred shareholders than it is to double the interest paid to its bankers and bondholders.So preferred stock is very different from common stock.

Frequently Asked Questions Learn more about Preferred Stock →
What does a Preferred Stock of €0.0 Mil mean?
Viva Biotech Holdings (FRA:VB0) has a Preferred Stock of €0.0 Mil as of Dec. 2025. Preferred Stock represents the par value of a company's preferred shares. View historical data on Viva Biotech Holdings and its competitors.
Is Viva Biotech Holdings' Preferred Stock too high?
Viva Biotech Holdings' current Preferred Stock is €0.0 Mil. Overall, Viva Biotech Holdings has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viva Biotech Holdings' Preferred Stock compare to VRTX and REGN?
Viva Biotech Holdings' Preferred Stock of €0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Preferred Stock for a Biotechnology company?
A good Preferred Stock depends on the Biotechnology industry context. However, Preferred Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Preferred Stock mean?
A high Preferred Stock can signal that a stock is expensive relative to its fundamentals. Preferred Stock represents the par value of a company's preferred shares. View historical data on Viva Biotech Holdings and its competitors. Viva Biotech Holdings's current Preferred Stock is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viva Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Viva Biotech Holdings (FRA:VB0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.08, compared to a current price of €0.13 — trading 62.5% above its estimated fair value. The current Preferred Stock is €0.0 Mil. Viva Biotech Holdings' overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Preferred Stock calculated?
Preferred Stock is calculated from a company's financial statements. For Viva Biotech Holdings (FRA:VB0), the current Preferred Stock is €0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Viva Biotech Holdings (FRA:VB0) Overvalued in 2026?

Based on GuruFocus' analysis, Viva Biotech Holdings stock appears to be overvalued. The current stock price of €0.13 is trading 62.5% above its estimated GF Value™ of €0.08. GuruFocus considers Viva Biotech Holdings to be Significantly Overvalued.

Key valuation signals for FRA:VB0:

  • Preferred Stock: €0.0 Mil
  • GF Value™: €0.08 vs. price of €0.13 (62.5% above fair value)
  • GF Score™: 42/100 with 5 warning signs

No single metric tells the full story. See the FRA:VB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Viva Biotech Holdings Business Description

Other Exchanges VBIZF:USA01873:Hong Kong
Address 735 Ziping Road, Pudong New District, Zhoupu Town, Shanghai, CHN, 201318
Viva Biotech Holdings is engaged in providing the structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development. The company operates in three reportable segments, Drug Discovery Services providing structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development; Contract Development Manufacture Organisation providing contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations; and commercialisation services; and Viva BioInnovator making strategic investments in biotechnology startup companies.
42GF Score

Get the complete analysis for FRA:VB0

Preferred Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.13
Price
€0.08
GF Value